Verastem (VSTM) 2025 Earnings Call Presentation

Verastem Oncology R&D Investor Event ASCO 2025 June 2, 2025 Disclaimers Forward-Looking Statements This presentation includes forward-looking statements about, among other things, Verastem Oncology's (the "Company") programs and product candidates, strategy, future plans and prospects, including statements related to the anticipated timing of a potential launch of avutometinib and defactinib in Low-Grade Serous Ovarian Cancer, the expected outcome and benefits of collaborations, including with GenFleet Ther ...